New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
07:14 EDTSPNCFinal results of Spectranetics study supports successful laser atherectomy use
Spectranetics announced final results from the Photo-Ablation using the Turbo-Booster and Excimer Laser for In-Stent Restenosis Treatment, or PATENT, study evaluating the safety and efficacy of the Spectranetics peripheral laser atherectomy catheters for the treatment of in-stent restenosis, or ISR, in the femoropopliteal artery in the leg. ISR occurs as a result of narrowing of the artery in patients who have undergone stenting for the treatment of peripheral arterial disease, or PAD. There is currently no FDA-cleared or approved device to treat peripheral in-stent restenosis, which remains a major unsolved medical problem. Ninety patients participated in this prospective, multi-center registry, which completed enrollment in December 2011 at five centers in Germany. The study evaluated extremely complex patients who had a previously failed stent procedure to address peripheral arterial disease. Final results presented indicate 82% and 52% freedom from target lesion revascularization, or TLR, at six and 12 months, respectively. Laser atherectomy demonstrated excellent midterm primary patency of 64% as compared to 37% with balloon angioplasty primary patency as published in previous clinical registries. This is a significant improvement considering the challenging nature of these patients.
News For SPNC From The Last 14 Days
Check below for free stories on SPNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
16:11 EDTSPNCSpectranetics gets FDA clearance for mechanical lead extraction devices
Subscribe for More Information
April 8, 2014
12:12 EDTSPNCOn The Fly: Midday Wrap
Subscribe for More Information
08:08 EDTSPNCSpectranetics sell-off a buying opportunity, says JPMorgan
Subscribe for More Information
07:29 EDTSPNCSpectranetics price target lowered to $30 from $35 at Canaccord
Subscribe for More Information
April 7, 2014
16:13 EDTSPNCSpectranetics lowers FY14 revenue view to $171.5M-$174M from $177.5M-$180M
Subscribe for More Information
16:10 EDTSPNCSpectranetics sees Q1 revenue $39.6M, consensus $41.42M
Subscribe for More Information
16:00 EDTSPNCSpectranetics trading halted, pending news
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use